| 1.375 -0.015 (-1.08%) | 10-28 12:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.74  |
1-year : | 1.93 |
| Resists | First : | 1.49 |
Second : | 1.65 |
| Pivot price | 1.45  |
|||
| Supports | First : | 1.22 |
Second : | 1.01 |
| MAs | MA(5) : | 1.39 |
MA(20) : | 1.45 |
| MA(100) : | 1.13 |
MA(250) : | 0.88 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.6 |
D(3) : | 13.5 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 2.07 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LXRX ] has closed above bottom band by 20.3%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.48 - 1.49 | 1.49 - 1.5 |
| Low: | 1.37 - 1.38 | 1.38 - 1.39 |
| Close: | 1.38 - 1.39 | 1.39 - 1.4 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Wed, 08 Oct 2025
Lexicon Pharmaceuticals Hosts Roundtable on Legislative Solutions for Chronic Pain Management - Quiver Quantitative
Wed, 08 Oct 2025
50M Americans with Chronic Pain: Lexicon Convenes Roundtable on Expanding Alternatives to PAIN Act - Stock Titan
Wed, 08 Oct 2025
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - Yahoo Finance
Thu, 02 Oct 2025
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28% - simplywall.st
Mon, 08 Sep 2025
FDA Update: Lexicon's Diabetes Drug Zynquista Gets New Clinical Data Support from 3 Major Centers - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 363 (M) |
| Held by Insiders | 1.8389e+008 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 28,380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.0547e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -206.5 % |
| Operating Margin | 12.9 % |
| Return on Assets (ttm) | -22.2 % |
| Return on Equity (ttm) | -65.4 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 526.29 |
| Sales Per Share | 4.7121e+007 |
| EBITDA (p.s.) | -2.04435e+007 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -102 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 4.73 |
| Dividend | 0 |
| Forward Dividend | 2.683e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|